BGBaorui Guo

Baorui Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Baorui Guo has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Jianning Zhang

    Senior Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China

    2 shared publications
  • Jiayu Liu

    Senior Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China

    2 shared publications
  • Ao Xu

    Senior Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China

    1 shared publication
  • Bingxian Wang

    Department of Neurosurgery, The First Medical Centre, Chinese PLA General Hospital, Beijing, 100853, China; PLA Medical School, Beijing, 100853, China

    1 shared publication
  • Gang Cheng

    Senior Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China

    1 shared publication
  • Huadong Wang

    NMPA Key Laboratory for Research and Evaluation of Viral Vector Technology in Cell and Gene Therapy Medicinal Products, Brain Cognition and Brain Disease Institute, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China

    1 shared publication

Latest Publications

  • Open Access

    Oncolytic Herpes Simplex Virus for Glioblastoma: Molecular Engineering, Tumor Microenvironment Barriers, and Clinical Translation

    by Jiayu Liu, Yuxin Wang, Zhao Gao, Tongtan Liu, Ao Xu, Wenxuan Li, Mei Li, Xiaomeng Song, Baorui Guo, Huadong Wang, et al.

    Glioblastoma (GBM) remains the most aggressive primary malignant brain tumor in adults, with limited survival benefit from the current standard of care consisting of maximal safe resection, radiotherapy, and temozolomide-based chemotherapy. The highly infiltrative growth pattern, profound intratumoral heterogeneity, and strongly immunosuppressive tumor microenvironment together contribute to therapeutic resistance and frequent recurrence. In this context, oncolytic herpes simplex virus (oHSV) has emerged as a promising therapeutic platform for glioblastoma because of its dual capacity to directly lyse tumor cells and stimulate antitumor immune responses. In addition, the large viral genome and well-characterized biology of herpes simplex virus enable extensive genetic engineering to improve tumor selectivity, safety, and immunomodulatory function. In this review, we summarize the molecular design strategies that have driven the development of oHSV for glioblastoma, including attenuation of neurovirulence, enhancement of tumor-selective replication, and arming with immune-stimulatory transgenes. We further discuss the major biological barriers within the GBM tumor microenvironment that continue to limit therapeutic efficacy, with particular attention given to representative engineered oHSV platforms and the lessons learned from preclinical and early-phase clinical studies. A dedicated section examines these barriers in detail, including restricted intratumoral viral spread, antiviral innate immunity, and immunosuppressive myeloid cell dominance. We also review current efforts to improve outcomes through rational combination strategies with radiotherapy, immune checkpoint blockade, cytokine modulation, and other multimodal approaches. Although encouraging advances have been achieved, the clinical translation of oHSV therapy for glioblastoma still faces substantial challenges in patient selection, delivery optimization, response assessment, and treatment integration. A deeper understanding of virus–host–tumor interactions and more precise engineering of viral platforms may help unlock the full potential of oHSV-based therapy. Overall, oHSV represents one of the most compelling translational approaches in glioblastoma and provides a valuable framework for the development of mechanism-driven viro-immunotherapy in neuro-oncology.


  • Ultra-early detection of S100B biomarkers using a nanophotonic biosensor with deep learning quantification: A clinical model based on EDAS patients

    by Jiayu Liu, Yuxin Wang, Wenying Lv, Zhao Gao, Shichao Su, Baorui Guo, Yanteng Li, Lei Liang, Bingxian Wang, Gang Cheng, et al.